Page 136 - Read Online
P. 136

Ding et al. Hepatoma Res 2018;4:12  I  http://dx.doi.org/10.20517/2394-5079.2018.07                                                  Page 5 of 8


                                                            d
                          0.5
                                           b                                                 TNF-α
                                                                      e
                                                                                             IL-1β
                          0.4
                                                   c
                                                                                             AFP
                                 a
                          0.3


                          0.2


                          0.1


                          0.0
                                  A                 B                 C                  D                 E                  F
                                                        Groups

               Figure 3. Expression of TNF-α, IL-1β and AFP by ELISA in six groups. Group A: non-transfected, non-treated cells; group B: transient
               β2GPI-and HBsAg-transfection without LPS treatment; group C: non-transfected cells treated with 100 ng/mL LPS; group D: transient
               β2GPI- and HBsAg-transfection and treated with 100 ng/mL LPS; group E: transient β2GPI-transfection and treated with 100 ng/mL
               LPS; group F: transient HBsAg-transfection and treated with 100 ng/mL LPS. Data presented as means ± SD. a: groups B, C, D, E, and F
               compared with group A, P < 0.05; b: group B compared with groups A, C, E, and F, P < 0.05; c: groups E and F compared with group C, P <
               0.05; d: group D compared with groups A, B, C, E, and F, P < 0.00; e: group E compared with group F, P > 0.05; f: group C compared with
               groups B, E, and F, P < 0.05. β2GPI: beta2-glycoprotein I; HBsAg: hepatitis B surface antigen; LPS: lipopolysaccharide

               C (590.4 ± 9.49) (P < 0.05). The level of NF-κB activation in group E and F were similar (P > 0.05). Taken
               together, these data suggest that LPS alone induced activation of NF-κB, which enhanced by either β2GPI- or
               HBsAg-transfection. However, the highest effect was seen in doubly-transfected cells, suggesting synergism
               between LPS, β2GPI and HBsAg with respect to activation of NF-κB in HCC.


               LPS induced increased expression of TNF-α, IL-1β, and AFP in β2GPI- and/or HBsAg-
               transfected cells
               Cell supernatants from the six groups were collected and levels of TNF-α, IL-1β and AFP were assayed

               24 h after transfection of respective recombinant plasmids. As depicted in Figure 3, groups B, C, D, E, and
               F induced expression of TNF-α, IL-1β and AFP more than did group A (P < 0.05). The highest expression
               levels of all three cytokines was seen in group D (doubly transfected with β2GPI and HBsAg and treated with
               LPS) (P < 0.001). The expression levels of IL-1β and AFP in group B was higher (P < 0.05) were higher than
               those of groups A, C, E, and F, while their expression in groups E and F were higher than those of group C
               (P < 0.05). The expression of TNF-α in group C was higher than that of groups B, E, and F (P < 0.05). TNF-α
               and IL-1β levels were similar in groups E and F (P > 0.05), while AFP in these groups were significantly
               higher than in group A (P < 0.05).



               DISCUSSION
               HCC, one of the most common tumors, is currently the fifth most common malignant tumor worldwide,
               with morbidity increasing every year. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are major causes
                      [10]
               of HCC . Therapeutic options include etiological treatment, resection, percutaneous ablation, trans-arterial
               chemoembolization (TACE), and targeted therapy. The overall efficacy of these therapies is poor, and five-
                                                                    [11]
               year survival rates for early treatment of HCC are not favorable . Therefore, understanding the pathogenesis
               of HCC (abnormal neovascularization, genomics, proteomics and signal transduction pathways) is necessary
               to understand how HCC occurs and to develop new therapeutic approaches.
   131   132   133   134   135   136   137   138   139   140   141